1. Market Research
  2. > Healthcare
  3. > Medical Device
  4. > In Vitro Diagnostics Market Trends

Next Generation Sequencing (NGS) Markets 2015

  • January 2015
  • 391 pages
  • Kalorama Information
Report ID: 2736754

Summary

Table of Contents

No business planner in biotechnology or diagnostic equipment or services can ignore the trend of sequencing, and particularly next-generation sequencing. This technology has enabled a wide scope of research and genetic analysis. The promise of DNA sequencing has attracted many companies, researchers, and investors. DNA sequencing has already become a large market, and clinical applications of DNA sequencing are being developed and commercialized. More than ever, marketers of advanced equipment and those investing in those companies need a resource to identify the specific developments in sequencing.

This report, Next-Generation Sequencing Markets (Systems, Consumables, Services, Acquisitions, Agreements, Competitive Analysis, Trends, Platforms, Applications, Brand Ownership) provides evidence of the promise and current excitement in the DNA sequencing market.


Tracking the Path of Sequencing to the Clinical Lab

Many improvements in sequencing technology are needed in order to make sequencing-based diagnostic tests widely available and used by all physicians, though DNA sequencing has successfully penetrated the research market. Applications of next generation sequencing in clinical laboratories and companies with CLIA-certified laboratories will continue to grow. The first next generation sequencing system and IVD tests have been cleared by the FDA, and more will follow. Some next generation sequencing companies are starting to develop and commercialize kits that can be produced and sold to clinical laboratories following the traditional in vitro diagnostic (IVD) model.


Reasons for Optimism

Over the years, the DNA sequencing field has gone through periods of excitement (referred to as hype) by some, followed by periods of disappointment as the hoped for advances have not materialized as quickly as hoped or promised.

The promise of DNA sequencing has attracted many companies, researchers, investors, and others. DNA sequencing has already become a large market, and clinical applications of DNA sequencing are being developed and commercialized. Evidence of the promise and current excitement with DNA sequencing can be seen with many recent events:

The DNA sequencing market is growing rapidly. In October 2014, market leader Illumina raised the company's full year 2014 guidance for investors to a revenue growth for the company of approximately 30% over the previous year.

Roche and Foundation Medicine announced an agreement that is worth up to $1.2 billion. Roche agreed to acquire a majority interest in Foundation Medicine for approximately $780 million. Roche also agreed to invest $250 million in Foundation Medicine, and to fund potentially more than $150 million of R&D
Companies are raising money: In just the first part of January 2015, In addition to Roche's investment in Foundation Medicine, 10X Genomics closed a $55.5 million Series B financing and Invitae filed for an initial public offering, These follow a busy 2014 year that saw many investments in next generation sequencing companies and companies with products or services related to next generation sequencing.

Agreements with pharmaceutical companies: Companies in the pharmaceutical industry have recognized the potential benefits of next generation sequencing as a research and development tool. During just part of 2015, Genentech announced two agreements, and Pfizer announced one.

Sequencing companies are starting to develop and commercialize kits that can be produced and sold to clinical laboratories following the traditional in vitro diagnostic (IVD) model. Illumina's MiSeqDx was the first cleared in vitro diagnostic (IVD) next generation sequencing system. MiSeqDx is also CE marked, and FDA-cleared tests are currently available on this platform.

These are just selected highlights of recent activities in this rapidly changing market. Because of these trends, Kalorama expects the market to grow from its current size of 2.2 billion to 5.6 billion. The entire market is broken out in detail in Kalorama's Next Generation Sequencing Markets.

This Informative Analysis Helps You Track These Developments, with Reliable Market Estimates

The report provides the world markets for next generation sequencing in U.S. dollars for 2014 to 2018. As part of its analysis, the following data points are provided.

DNA Sequencing Systems Market Size and Forecast
DNA Sequencing Consumables Market, Size and Forecast
DNA Sequencing Services Market, Size and Forecast
Sequencing Market €“ Geographical Distribution (US, Europe, Asia, ROW)
Market Share by Major Competitor
Brand Ownership by Platform
DNA Sequencing Market €“ Research versus Clinical Applications
The sequencing market includes capillary electrophoresis sequencing systems (based on the early Sanger sequencing method) and also the rapidly growing next generation sequencing market. The market estimate includes both sequencing instruments plus consumables.

Who's Doing What In Sequencing: Superior Company Profiling

Competitor participation is an important part of the shaping of this market and the report devotes considerable detail to competitive analysis. Driven by the promise of clinical diagnostic applications, the DNA sequencing market is growing rapidly and companies are raising money. In early 2015 and throughout a busy 2014 there were many investments in next generation sequencing companies and companies with products or services related to next generation sequencing. Pharmaceutical companies, for example, have recognized the potential benefits of next generation sequencing as a research and development tool. The report provides product information and financial information for over 100 companies that are involved in next generation sequencing including:

10X Genomics
23andMe, Inc.
Adaptive Biotechnologies Corporation
Admera Health (A GENEWIZ Company)
Advanced Biological Laboratories, S.A.
Agilent Technologies Inc.
AltheaDx Diagnostics, Inc.
Ambry Genetics Corp.
Aperiomics, Inc.
Appistry, Inc.
Asuragen, Inc.
Athena Diagnostics, Inc. (A Quest Diagnostics Business)
Base4 Innovation Ltd.
Beckman Coulter, Inc. (Subsidiary of Danaher Corporation)
BGI-Shenzhen
Bina Technologies, Inc. (Acquired by Roche)
BioDiscovery, Inc.
Bioinnovation Solutions SA
Biomatters Ltd.
bioMerieux SA
bioTheranostics (A bioMerieux Company)
Cancer Genetics, Inc.
CareDx, Inc.
Caris Life Sciences
Chronix Biomedical, Inc.
CLC bio (A QIAGEN Company)
Complete Genomics (A BGI Company)
Courtagen Life Sciences, Inc.
Cypher Genomics, Inc.
DioGenix, Inc.
DNA Electronics Ltd.
DNASTAR, Inc.
Eurofins Genomics
Eurofins MWG Operon Inc. (A Eurofins Genomics Company)
Expression Analysis, Inc. (A Quintiles Company)
Fluidigm Corporation
Foundation Medicine, Inc.
GATC Biotech AG
GenapSys
GenDx
Gene by Gene, Ltd.
Genection, Inc. (An Invivoscribe Company)
GeneDx
GeneInsight, Inc.
GENEWIZ Inc.
Genia Technologies, Inc. (Acquired by Roche)
GenoLogics Life Sciences Software
Genomic Diagnostics Technologies
GenomOncology
Genoptix (A Novartis Company)
GigaGen, Inc.
GnuBIO, Inc. (Acquired by Bio-Rad Laboratories, Inc.)
Good Start Genetics, Inc.
HTG Molecular Diagnostics
Human Longevity, Inc.
Igenbio, Inc.
Illumina, Inc.
Innovations Exchange Pte Ltd (INEX)
iGene„¢ Diagnostics Pte Ltd (an INEX Company)
Insight Genetics, Inc.
InSilixa, Inc.
Intel Corporation
Intelligent Bio-Systems, Inc. (A QIAGEN Company)
Invivoscribe Technologies, Inc.
iRepertoire, Inc.
Knome Inc.
Laboratory Corporation of America (LabCorp)
LaserGen, Inc.
LifeCodexx AG (Subsidiary of GATC Biotech AG)
Life Technologies Corporation (Acquired by Thermo Fischer Scientific Inc.)
Mayo Medical Laboratories and Mayo Clinic
MolecularMD Corporation
Multiplicom NV
Nabsys, Inc.
Natera, Inc.
NeoGenomics, Inc./NeoGenomics Laboratories
NetBio, Inc.
NewGene Ltd.
NextCODE Health
NobleGen Biosciences, Inc.
N-of-One, Inc.
OncoDNA SA
OncoPlex Diagnostics (OncoPlexDx)
Oncospire Genomics
One Lambda, Inc. (A Thermo Fisher Scientific Brand)
Oxford Gene Technology
Oxford Nanopore Technologies Ltd.
Pacific Biosciences
Parabase Genomics
Pathway Genomics Corporation
PerkinElmer, Inc.
Personal Genome Diagnostics, Inc.
Personalis, Inc.
PicoSeq
Population Genetics Technologies Ltd.
QIAGEN N.V.
QuantuMDx Group
Quest Diagnostics
RainDance Technologies, Inc.
Response Genetics, Inc.
Roche
SeqLL, LLC
Sequenta, Inc.
Siemens Healthcare Diagnostics
Siemens
Sirona Genomics
SoftGenetics, LLC
Stratos Genomics Inc.
Swift Biosciences, Inc.
Symbiodx
Sysmex Inostics GmbH
Thermo Fisher Scientific, Inc.
Vela Diagnostics
WaferGen Biosystems, Inc.
ZS Genetics, Inc.

The information presented in this report is derived from publicly available information sources such as company reports and announcements, government reports and databases, medical organization reports, medical associations, and other publications. The analysis is based on the author's industry knowledge combined with literature searches and discussions with industry professionals and experts in the areas of point-of-care tests, decentralized healthcare and healthcare economics.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Cell-based Assays Market by Product (Reagents, Assay Kits, Microplates, Cell Lines, Service), Application (Research, Drug Discovery, ADME Studies, Toxicology), End User, and Region - Global Forecast to 2022

  • $ 5650
  • Industry report
  • July 2017
  • by MarketsandMarkets

“Cell-based assays market projected to grow at a CAGR of 8.4% during the forecast period” The global cell-based assays market is expected to reach USD 19.92 billion by 2022, at a CAGR of 8.4% from ...

Next-generation Sequencing: Emerging Clinical Applications and Global Markets

  • $ 5501
  • Industry report
  • June 2017
  • by BCC Research

• The global clinical next-generation sequencing (NGS) market reached $2.7 billion in 2016. This market is expected to grow at a compound annual growth rate (CAGR) of 27%, from nearly $3.2 billion in ...

Cell-based Assays: Technologies and Global Markets

  • $ 5501
  • Industry report
  • July 2017
  • by BCC Research

REPORT HIGHLIGHTS • The global market for cell-based assays reached $15.2 billion in 2015. This market is expected to increase from $17.1 billion in 2016 to nearly $28.4 billion in 2021 at a compound ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.